Status:
UNKNOWN
Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea
Lead Sponsor:
Federal University of São Paulo
Conditions:
Seborrhea
Seborrheic Dermatitis
Eligibility:
All Genders
18-40 years
Phase:
PHASE4
Brief Summary
Oral isotretinoin is the gold standard drug to treat moderate to severe acne. Other indications like seborrhea, seborrheic dermatitis have been suggested. There is risk of reversible mucocutaneous sid...
Detailed Description
Oral isotretinoin is a retinoid that controls gene expression related to cellular proliferation, differentiation, with specific action over sebocytes, reducting sebaceous gland size and secretion rate...
Eligibility Criteria
Inclusion
- consent form signature
- presence of seborrhea and / or seborrheic dermatitis on face and scalp
- good health
- no previous treatment with oral isotretinoin in the last 6 months
- normal laboratorial tests: pregnancy test, blood counting, transaminases and lipide profile
- concordance on use of two anticonceptional methods, during and until one month after the end of the study
Exclusion
- difficulty to follow study conditions
- pregnancy risk
- diabetes
- collagen diseases
- bone or muscles diseases
- alcohol abuse
- hypervitaminosis A
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2012
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01139749
Start Date
October 1 2011
End Date
December 1 2012
Last Update
October 12 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federal University of Sao Paulo - Dermatology Department - Cosmetic Dermatology Unit
São Paulo, São Paulo, Brazil, 04022-000